RDHL - レッドヒル・バイオファ―マ (Redhill Biopharma Ltd.) レッドヒル・バイオファ―マ

 RDHLのチャート


 RDHLの企業情報

symbol RDHL
会社名 Redhill Biopharma Ltd Ramat Gan (レッドヒル・バイオファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    医療関連(Health Care)
概要 事業概要 --   レッドヒル・バイオファ―マは、イスラエルのバイオ製薬会社。胃腸癌を含む炎症性および胃腸疾患の治療用に、後期の臨床段階にある独自の経口投与薬剤を開発、買収に注力する。イスラエル、米国、カナダ、欧州で事業を展開。同社の製品パイプラインは、後期の臨床段階にある8薬の治療候補で構成される。   RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, Movantik® for opioid-induced constipation in adults, Talicia® for the treatment of Helicobacter pylori (H. pylori) infection in adults, and Aemcolo® for the treatment of travelers' diarrhea in adults. RedHill's key clinical late-stage development programs include: (i) RHB-204, with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (ii) opaganib (Yeliva®, ABC294640), a first-in-class SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-107 (upamostat), a serine protease inhibitor in a U.S. Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; (v) RHB-102 (Bekinda®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi) RHB-106, an encapsulated bowel preparation.
本社所在地 21 Ha'arba'a Street Tel-Aviv 64739 ISR
代表者氏名
代表者役職名
電話番号
設立年月日 40026
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 74人
url www.redhillbio.com
nasdaq_url https://www.nasdaq.com/symbol/rdhl
adr_tso 15297124
EBITDA EBITDA ー
終値(lastsale) 8.38
時価総額(marketcap) 128189899.12
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 RDHLのテクニカル分析


 RDHLのニュース

   RedHill Biopharma Says Opaganib Can Potentially Work Against COVID-19 Omicron Subvariants  2022/04/11 19:46:29 Benzinga
RedHill Biopharma Ltd''s (NASDAQ: RDHL ) opaganib (ABC294640), an oral drug candidate for hospitalized COVID-19 patients, demonstrated potent in vitro efficacy against the omicron variant while maintaining host cell viability. The Company says that based on the new and previously announced data, opaganib''s dual antiviral and anti-inflammatory suggested mechanism is expected to act independently of viral spike protein mutations … Full story available on Benzinga.com
   RedHill pill shows promise vs Omicron; mRNA vaccines appear effective in those with well-controlled HIV  2022/04/11 19:05:16 Financial Post
The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review. Experimental pill shows promise against Omicron An experimental drug being developed by RedHill Biopharma Ltd that improved outcomes in a randomized trial involving […]
   RDHL stock in focus on lab data for COVID-19 drug against Omicron (NASDAQ:RDHL)  2022/04/11 13:31:44 Seeking Alpha
Israel-based RedHill Biopharma (RDHL) said on Monday that its investigational oral COVID therapy opaganib was effective against the Omicron variant and maintained the viability of…
   RedHill Biopharma Ltd Announces Potent Omicron Inhibition with RedHill''s Opaganib  2022/04/11 12:02:00 Wallstreet:Online
Oral opaganib''s reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The University of Hong Kong School of Public Health, …
   RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q4 2021 Results - Earnings Call Transcript  2022/03/17 19:03:04 Seeking Alpha
   RedHill Biopharma Says Opaganib Can Potentially Work Against COVID-19 Omicron Subvariants  2022/04/11 19:46:29 Benzinga
RedHill Biopharma Ltd''s (NASDAQ: RDHL ) opaganib (ABC294640), an oral drug candidate for hospitalized COVID-19 patients, demonstrated potent in vitro efficacy against the omicron variant while maintaining host cell viability. The Company says that based on the new and previously announced data, opaganib''s dual antiviral and anti-inflammatory suggested mechanism is expected to act independently of viral spike protein mutations … Full story available on Benzinga.com
   RedHill pill shows promise vs Omicron; mRNA vaccines appear effective in those with well-controlled HIV  2022/04/11 19:05:16 Financial Post
The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review. Experimental pill shows promise against Omicron An experimental drug being developed by RedHill Biopharma Ltd that improved outcomes in a randomized trial involving […]
   RDHL stock in focus on lab data for COVID-19 drug against Omicron (NASDAQ:RDHL)  2022/04/11 13:31:44 Seeking Alpha
Israel-based RedHill Biopharma (RDHL) said on Monday that its investigational oral COVID therapy opaganib was effective against the Omicron variant and maintained the viability of…
   RedHill Biopharma Ltd Announces Potent Omicron Inhibition with RedHill''s Opaganib  2022/04/11 12:02:00 Wallstreet:Online
Oral opaganib''s reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The University of Hong Kong School of Public Health, …
   RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q4 2021 Results - Earnings Call Transcript  2022/03/17 19:03:04 Seeking Alpha
   RedHill Biopharma Says Opaganib Can Potentially Work Against COVID-19 Omicron Subvariants  2022/04/11 19:46:29 Benzinga
RedHill Biopharma Ltd''s (NASDAQ: RDHL ) opaganib (ABC294640), an oral drug candidate for hospitalized COVID-19 patients, demonstrated potent in vitro efficacy against the omicron variant while maintaining host cell viability. The Company says that based on the new and previously announced data, opaganib''s dual antiviral and anti-inflammatory suggested mechanism is expected to act independently of viral spike protein mutations … Full story available on Benzinga.com
   RedHill pill shows promise vs Omicron; mRNA vaccines appear effective in those with well-controlled HIV  2022/04/11 19:05:16 Financial Post
The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review. Experimental pill shows promise against Omicron An experimental drug being developed by RedHill Biopharma Ltd that improved outcomes in a randomized trial involving […]
   RDHL stock in focus on lab data for COVID-19 drug against Omicron (NASDAQ:RDHL)  2022/04/11 13:31:44 Seeking Alpha
Israel-based RedHill Biopharma (RDHL) said on Monday that its investigational oral COVID therapy opaganib was effective against the Omicron variant and maintained the viability of…
   RedHill Biopharma Ltd Announces Potent Omicron Inhibition with RedHill''s Opaganib  2022/04/11 12:02:00 Wallstreet:Online
Oral opaganib''s reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The University of Hong Kong School of Public Health, …
   RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q4 2021 Results - Earnings Call Transcript  2022/03/17 19:03:04 Seeking Alpha

 関連キーワード  (― 米国株 レッドヒル・バイオファ―マ RDHL Redhill Biopharma Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)